No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 19 of the 33 quarters in the window, leaving 14 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.3x · 10Y median 3.1x · 18th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 34
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:07:02.800Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Intelligent Bio Solutions Inc. (INBS) stock was $1.68 as of Oct 6, 2026, 10:05 AM EDT, up 0.60% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -85.6% · 3-year avg -67.1%/yr · 5-year avg -80.3%/yr
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers.
Medical - Devices · New York City, NY
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-1.31
Revenue Est.
$1.40M
Last Quarter Results
EPS
$-1.34
vs Estimate
$-1.58
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1INBS | $5.57M | $1.68 | +0.60% | -85.59% | -80.26% | N/A | N/A |
| 2ACXP | $5.63M | $1.31 | -0.05% | -71.04% | -57.41% | N/A | vs INBS |
| 3ALZN | $5.36M | $1.41 | +0.00% | -44.11% | -79.14% | N/A | vs INBS |
| 4LNAI | $5.36M | $1.18 | +3.72% | -88.84% | N/A | N/A | vs INBS |
| 5CUPR | $5.89M | $2.20 | -2.35% | -74.72% | N/A | N/A | vs INBS |
| 6BMGL | $5.24M | $3.35 | +5.68% | -83.45% | N/A | N/A | vs INBS |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$1.20M
vs Estimate
$1.22M
Consensus Rating
Based on 1 analyst
Average Price Target
$12.00
+614.3% upside
Low
$12.00
Current
$1.68
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.31 | $-1.31 | $-1.31 | 1 |
| Quarter ending Dec 2026 | $-1.36 | $-1.36 | $-1.36 | 1 |
| Quarter ending Mar 2027 | $-1.33 | $-1.33 | $-1.33 | 1 |
| Quarter ending Jun 2027 | $-1.18 | $-1.18 | $-1.18 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-5.18 | $-5.18 | $-5.18 | 1 |
| FY 2028 | $-4.06 | $-4.06 | $-4.06 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.40M | $1.40M | $1.40M | 1 |
| Quarter ending Dec 2026 | $1.40M | $1.40M | $1.40M | 1 |
| Quarter ending Mar 2027 | $1.50M | $1.50M | $1.50M | 1 |
| Quarter ending Jun 2027 | $1.80M | $1.80M | $1.80M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $6.10M | $6.10M | $6.10M | 1 |
| FY 2028 | $8.80M | $8.80M | $8.80M | 1 |
